Loading patent…
AssigneeAllergan, Inc.
InventorsGlenn T. Huang, Brittany Jackson, James A. Burke, Ton Lin, Patrick M. Hughes, Larry A. Wheeler, Rosy Sheng Donn
Estimating the term…
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
-42. (canceled)
A method of treating non-exudative age related macular degeneration in an eye of a patient, comprising the step of placing a solid extruded biodegradable intraocular implant in an eye of the patient to provide a therapeutically effective amount of an alpha-2 adrenergic receptor agonist to the patient for at least about one week, wherein the implant comprises the alpha-2 adrenergic receptor agonist associated with a biodegradable polymer matrix that releases alpha-2 adrenergic receptor agonist at a rate effective to sustain release of an amount of the alpha-2 adrenergic receptor agonist from the implant for a time effective to treat non-exudative age related macular degeneration in the eye in which the implant is placed, and wherein the polymer matrix comprises two different polylactide polymers.
Dependencies are inferred from the claim text.